Other Relevant Articles - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Volume brings value
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention
Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Original Research

2019 Feb 12;139(7):863-873.

JOURNAL：Circulation.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Fanaroff AC, Clare R, Pieper KS et al.

7627

Keywords: cause of death; clinical trial; death; follow-up studies; quality control

FULL TEXT PDF